Found: 11
Select item for more details and to access through your institution.
Expression of CD304/neuropilin‐1 in adult b‐cell lymphoblastic leukemia/lymphoma and its utility for the measurable residual disease assessment.
- Published in:
- International Journal of Laboratory Hematology, 2021, v. 43, n. 5, p. 990, doi. 10.1111/ijlh.13456
- By:
- Publication type:
- Article
Mimics and artefacts of measurable residual disease in a highly sensitive multicolour flow cytometry assay for B‐lymphoblastic leukaemia/lymphoma: critical consideration for analysis of measurable residual disease.
- Published in:
- British Journal of Haematology, 2022, v. 196, n. 2, p. 374, doi. 10.1111/bjh.17801
- By:
- Publication type:
- Article
Utility of leukocyte‐associated immunoglobulin‐like receptor‐1 (CD305) in flow cytometric detection of minimal bone marrow involvement by B‐cell non‐Hodgkin lymphoma.
- Published in:
- Cytometry. Part B, 2024, v. 106, n. 5, p. 359, doi. 10.1002/cyto.b.22193
- By:
- Publication type:
- Article
Expression levels and patterns of B‐cell maturation antigen in newly diagnosed and relapsed multiple myeloma patients from Indian subcontinent.
- Published in:
- Cytometry. Part B, 2022, v. 102, n. 6, p. 462, doi. 10.1002/cyto.b.22099
- By:
- Publication type:
- Article
Detecting hypodiploidy with endoreduplication and masked hypodiploidy in B‐cell acute lymphoblastic leukemia using multicolor flow cytometry.
- Published in:
- Cytometry. Part B, 2022, v. 102, n. 3, p. 199, doi. 10.1002/cyto.b.22063
- By:
- Publication type:
- Article
Immunophenotypic shift in the B‐cell precursors from regenerating bone marrow samples: A critical consideration for measurable residual disease assessment in B‐lymphoblastic leukemia.
- Published in:
- Cytometry. Part B, 2021, v. 100, n. 4, p. 434, doi. 10.1002/cyto.b.21951
- By:
- Publication type:
- Article
Eleven‐marker 10‐color flow cytometric assessment of measurable residual disease for T‐cell acute lymphoblastic leukemia using an approach of exclusion.
- Published in:
- Cytometry. Part B, 2021, v. 100, n. 4, p. 421, doi. 10.1002/cyto.b.21939
- By:
- Publication type:
- Article
A High‐Sensitivity 10‐Color Flow Cytometric Minimal Residual Disease Assay in B‐Lymphoblastic Leukemia/Lymphoma Can Easily Achieve the Sensitivity of 2‐in‐10<sup>6</sup> and Is Superior to Standard Minimal Residual Disease Assay: A Study of 622 Patients
- Published in:
- Cytometry. Part B, 2020, v. 98, n. 1, p. 57, doi. 10.1002/cyto.b.21831
- By:
- Publication type:
- Article
15‐color highly sensitive flow cytometry assay for post anti‐CD19 targeted therapy (anti‐CD19‐CAR‐T and blinatumomab) measurable residual disease assessment in B‐lymphoblastic leukemia/lymphoma: Real‐world applicability and challenges
- Published in:
- European Journal of Haematology, 2024, v. 112, n. 1, p. 122, doi. 10.1111/ejh.14102
- By:
- Publication type:
- Article
Comprehensive immune cell profiling depicts an early immune response associated with severe coronavirus disease 2019 in cancer patients.
- Published in:
- Immunology & Cell Biology, 2022, v. 100, n. 1, p. 61, doi. 10.1111/imcb.12504
- By:
- Publication type:
- Article
Critical Role of Flow Cytometric Immunophenotyping in the Diagnosis, Subtyping, and Staging of T-Cell/NK-Cell Non-Hodgkin's Lymphoma in Real-World Practice: A Study of 232 Cases From a Tertiary Cancer Center in India.
- Published in:
- Frontiers in Oncology, 2022, v. 12, p. 1, doi. 10.3389/fonc.2022.779230
- By:
- Publication type:
- Article